1. Home
  2. Analysis
  3. Zolpidem
  4. Type-iii-immune-complex-mediated-reaction

Zolpidem and Type iii immune complex mediated reaction - a phase IV clinical study of FDA data

Summary:

Type iii immune complex mediated reaction is found among people who take Zolpidem, especially for people who are male, 50-59 old.

The phase IV clinical study analyzes which people take Zolpidem and have Type iii immune complex mediated reaction. It is created by eHealthMe based on reports of 80,705 people who have side effects when taking Zolpidem from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 22, 2023

80,705 people reported to have side effects when taking Zolpidem.
Among them, 8 people (0.01%) have Type iii immune complex mediated reaction.

What is Zolpidem?

Zolpidem has active ingredients of zolpidem tartrate. It is often used in insomnia. eHealthMe is studying from 82,981 Zolpidem users for its effectiveness, alternative drugs and more.

What is Type iii immune complex mediated reaction?

Type iii immune complex mediated reaction is found to be associated with 335 drugs and 194 conditions by eHealthMe.

Number of Zolpidem and Type iii immune complex mediated reaction reports submitted per year:

Could Zolpidem cause Type iii immune complex mediated reaction?

Gender of people who have Type iii immune complex mediated reaction when taking Zolpidem *:

  • female: 14.29 %
  • male: 85.71 %

Age of people who have Type iii immune complex mediated reaction when taking Zolpidem *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 14.29 %
  • 50-59: 85.71 %
  • 60+: 0.0 %

Common drugs people take besides Zolpidem *:

  1. Perphenazine: 7 people, 87.50%
  2. Alprazolam: 7 people, 87.50%
  3. Atorvastatin Calcium: 2 people, 25.00%
  4. Xolair: 1 person, 12.50%
  5. Tegretol: 1 person, 12.50%
  6. Fluoxetine: 1 person, 12.50%
  7. Diphenhydramine Hydrochloride: 1 person, 12.50%

Common side effects people have besides Type iii immune complex mediated reaction *:

  1. Urticaria (rash of round, red welts on the skin that itch intensely): 5 people, 62.50%
  2. Joint Pain: 5 people, 62.50%
  3. Breathing Difficulty: 4 people, 50.00%
  4. Swallowing Difficulty: 4 people, 50.00%
  5. Diarrhea: 4 people, 50.00%
  6. Rashes (redness): 4 people, 50.00%
  7. Rash Pruritic (redness with itching): 4 people, 50.00%
  8. Swelling: 3 people, 37.50%
  9. Fever: 2 people, 25.00%
  10. White Blood Cell Count Abnormal: 1 person, 12.50%

Common conditions people have *:

  1. Urticaria Chronic (long lasting rash of round, red welts on the skin that itch intensely): 1 person, 12.50%
  2. Hypersensitivity: 1 person, 12.50%

* Approximation only. Some reports may have incomplete information.

Do you take Zolpidem and have Type iii immune complex mediated reaction?

Check whether Type iii immune complex mediated reaction is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Related studies

How severe was Type iii immune complex mediated reaction and when was it recovered:

Expand to all the drugs that have ingredients of zolpidem tartrate:

Alternative drugs to, pros and cons of Zolpidem:

Common Zolpidem side effects:

Browse all side effects of Zolpidem:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Type iii immune complex mediated reaction treatments and more:

COVID vaccines that are related to Type iii immune complex mediated reaction:

All the drugs that are associated with Type iii immune complex mediated reaction:

All the conditions that are associated with Type iii immune complex mediated reaction:

How the study uses the data?

The study uses data from the FDA. It is based on zolpidem tartrate (the active ingredients of Zolpidem) and Zolpidem (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.